Stock P09 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Real-time Estimate Tradegate
Other stock markets
 12:32:37 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.236 EUR -1.29% Intraday chart for Pacific Biosciences of California, Inc. -9.70% -85.93%
Apr. 22 JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight MT
Apr. 18 Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT

Evolution of the average Target Price on Pacific Biosciences of California, Inc.

Price target over the last 5 years

History of analyst recommendation changes

821f41ad205f6d88bb.cSWltLha8wKBCsh6UYAChSKJlL4n7BNjRQunDifOsvU.HUDi1-9ow2jEW60jE8E0s3Wx8ecT2lwzA07uZWL20bcZdpXS8Dm8ddRkiQ~0604eddfd845ac4807677a6ef890db15

Analyst Recommendations on Pacific Biosciences of California, Inc.

JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7 MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating MT
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating MT
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating MT
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating MT
Guggenheim Initiates Pacific Biosciences of California With Neutral Rating MT
UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13 MT
Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating MT
Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14 MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating MT
Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating MT
Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target MT
UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating MT
Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target MT
Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating MT
Barclays Initiates Pacific Biosciences of California at Equalweight With $14 Price Target MT
Morgan Stanley Raises Pacific Biosciences of California's Price Target to $12 From $10, Maintains Equalweight Rating MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $17 From $15, Maintains Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating MT
TD Cowen Upgrades Pacific Biosciences of California to Outperform From Market Perform, Adjusts Price Target to $15 From $13 MT
UBS Adjusts Pacific Biosciences of California's Price Target to $12 From $13, Maintains Neutral Rating MT
UBS Initiates Coverage on Pacific Biosciences of California With Neutral Rating, $13 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
1.36 USD
Average target price
5.818 USD
Spread / Average Target
+327.81%
High Price Target
13 USD
Spread / Highest target
+855.88%
Low Price Target
2.5 USD
Spread / Lowest Target
+83.82%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pacific Biosciences of California, Inc.

JPMorgan Chase
Scotiabank
Goldman Sachs
TD Cowen
UBS
Guggenheim
Piper Sandler
Cantor Fitzgerald
Morgan Stanley
Barclays
Bernstein
Canaccord Genuity
J.P. Morgan Chase

Ratings for Pacific Biosciences of California, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PACB Stock
  4. P09 Stock
  5. Consensus Pacific Biosciences of California, Inc.